QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:AEMD

Aethlon Medical Stock Forecast, Price & News

$1.99
+0.08 (+4.19 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.83
Now: $1.99▼
$2.08
50-Day Range
$1.91
MA: $2.49▼
$3.08
52-Week Range
$1.18
Now: $1.99▼
$3.73
Volume445,231 shs
Average Volume662,619 shs
Market Capitalization$24.13 million
P/E RatioN/A
Dividend YieldN/A
Beta0.66
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.
Aethlon Medical logo

Headlines

Aethlon Medical to Participate in Two Upcoming Healthcare Investor Conferences
March 1, 2021 |  finance.yahoo.com
Aethlon Medical, Inc. (AEMD) CEO Dr. Chuck Fisher on Q3 2021 Results - Earnings Call Transcript
February 12, 2021 |  seekingalpha.com
AEMD: Company Provides Update on Studies and Business Outlook
February 11, 2021 |  finance.yahoo.com
Aethlon Medical (NASDAQ:AEMD) Is In A Good Position To Deliver On Growth Plans
February 7, 2021 |  finance.yahoo.com
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 10, 2021
February 4, 2021 |  finance.yahoo.com
AEMD: Establishing The Infrastructure To Support Expanding Opportunities
January 29, 2021 |  finance.yahoo.com
Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. Discusses Treatment of Life-Threatening Conditions Induced by Cytokine Storm Syndrome
January 25, 2021 |  marketwatch.com
Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
January 6, 2021 |  finance.yahoo.com
Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference
January 4, 2021 |  finance.yahoo.com
Stock Alert: Aethlon Medical Jumps 45%
December 16, 2020 |  nasdaq.com
Aethlon names Charles J. Fisher, Jr., M.D. as CEO
November 3, 2020 |  seekingalpha.com
AEMD: Oncology EFS Open For Enrollment
October 29, 2020 |  finance.yahoo.com
Aethlon Medical, Inc. (AEMD) CEO Tim Rodell on Q2 2021 Results - Earnings Call Transcript
October 29, 2020 |  seekingalpha.com
AEMD: Advancing The Hemopurifier in Two Feasibility Studies
October 23, 2020 |  finance.yahoo.com
Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on October 28, 2020
October 23, 2020 |  finance.yahoo.com
12 Healthcare Stocks Moving In Tuesday's After-Market Session
October 15, 2020 |  benzinga.com
Aethlon Medical to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 9, 2020 |  finance.yahoo.com
Aethlon Medical to Present at the LD Micro 500 Virtual Conference
August 27, 2020 |  finance.yahoo.com
We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate
August 11, 2020 |  finance.yahoo.com
Aethlon Medical Inc
July 22, 2020 |  www.bloomberg.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AEMD
Previous Symbol
CUSIPN/A
CIK773910
Webwww.aethlonmedical.com
Phone858-459-7800
Employees8
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio9.90
Quick Ratio9.90

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$650,000.00
Price / Sales37.12
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.99 per share
Price / Book2.01

Profitability

EPS (Most Recent Fiscal Year)($1.87)
Net Income$-6,390,000.00
Net MarginsN/A
Return on Equity-55.32%
Return on Assets-49.72%

Miscellaneous

Outstanding Shares12,124,000
Market Cap$24.13 million
Next Earnings Date6/24/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.37 out of 5 stars

Medical Sector

669th out of 1,971 stocks

Surgical & Medical Instruments Industry

74th out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.99
+0.08 (+4.19 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AEMD News and Ratings via Email

Sign-up to receive the latest news and ratings for AEMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aethlon Medical (NASDAQ:AEMD) Frequently Asked Questions

Is Aethlon Medical a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aethlon Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Aethlon Medical stock.
View analyst ratings for Aethlon Medical or view top-rated stocks.

What stocks does MarketBeat like better than Aethlon Medical?

Wall Street analysts have given Aethlon Medical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aethlon Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aethlon Medical's next earnings date?

Aethlon Medical is scheduled to release its next quarterly earnings announcement on Thursday, June 24th 2021.
View our earnings forecast for Aethlon Medical.

How were Aethlon Medical's earnings last quarter?

Aethlon Medical, Inc. (NASDAQ:AEMD) announced its quarterly earnings results on Tuesday, February, 9th. The medical equipment provider reported ($0.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.05.
View Aethlon Medical's earnings history.

How has Aethlon Medical's stock price been impacted by Coronavirus?

Aethlon Medical's stock was trading at $1.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AEMD shares have increased by 0.0% and is now trading at $1.99.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AEMD?

1 Wall Street analysts have issued 12 month price objectives for Aethlon Medical's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Aethlon Medical's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 201.5% from the stock's current price.
View analysts' price targets for Aethlon Medical or view top-rated stocks among Wall Street analysts.

Who are Aethlon Medical's key executives?

Aethlon Medical's management team includes the following people:
  • Dr. Charles J. Fisher Jr., CEO, Director & Member of Extracorporeal Therapy Advisory Board (Age 74, Pay $124k)
  • Mr. James B. Frakes, CFO, Sr. VP of Fin. & Sec. (Age 64, Pay $354.75k)
  • Mr. Guy F. Cipriani BS (Eng.), MBA, Sr. VP, Chief Bus. Officer & Director (Age 50, Pay $34k)
  • Mr. Sunil Sawhney, Head of Clinical Studies
  • Mr. Steven P. Larosa, Chief Medical Officer
  • Dr. Richard H. Tullis, Consultant (Age 76)

Who are some of Aethlon Medical's key competitors?

Some companies that are related to Aethlon Medical include SANUWAVE Health (SNWV), Brainsway (BWAY), LENSAR (LNSR), Pro-Dex (PDEX), InspireMD (NSPR), Nephros (NEPH), Delcath Systems (DCTH), Sensus Healthcare (SRTS), AIT Therapeutics (AITB), Nephros (NEPHD), STRATA Skin Sciences (SSKN), Plus Therapeutics (PSTV), Sintx Technologies (SINT), Motus GI (MOTS) and Daxor (DXR).
View all of AEMD's competitors.

What other stocks do shareholders of Aethlon Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Amarin (AMRN), Nokia (NOK), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), CRISPR Therapeutics (CRSP), Novavax (NVAX), OrganiGram (OGI), AT&T (T) and Aurora Cannabis (ACB).

What is Aethlon Medical's stock symbol?

Aethlon Medical trades on the NASDAQ under the ticker symbol "AEMD."

Who are Aethlon Medical's major shareholders?

Aethlon Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cardan Capital Partners LLC (0.13%).
View institutional ownership trends for Aethlon Medical.

Which institutional investors are buying Aethlon Medical stock?

AEMD stock was purchased by a variety of institutional investors in the last quarter, including Cardan Capital Partners LLC.
View insider buying and selling activity for Aethlon Medical or or view top insider-buying stocks.

How do I buy shares of Aethlon Medical?

Shares of AEMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aethlon Medical's stock price today?

One share of AEMD stock can currently be purchased for approximately $1.99.

How much money does Aethlon Medical make?

Aethlon Medical has a market capitalization of $24.13 million and generates $650,000.00 in revenue each year. The medical equipment provider earns $-6,390,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

How many employees does Aethlon Medical have?

Aethlon Medical employs 8 workers across the globe.

What is Aethlon Medical's official website?

The official website for Aethlon Medical is www.aethlonmedical.com.

Where are Aethlon Medical's headquarters?

Aethlon Medical is headquartered at 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA, 92123.

How can I contact Aethlon Medical?

Aethlon Medical's mailing address is 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-459-7800 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.